

<b>Reference:</b>	FOI.13296.23
<b>Subject:</b>	Arthritis treatments
<b>Date of Request:</b>	1 December 2023

**Requested:**

- In the past 12 months, how many patients have been treated (for any disease) with the following:
  - Anakinra (Kineret)
  - Canakinumab (Ilaris)
- In the past 12 months, how many Adult Onset Still's Disease (AODS) patients have been treated with the following:
  - Anakinra (Kineret)
  - Canakinumab (Ilaris)
- In the past 12 months, how many Juvenile Arthritis with Systemic Onset (SJIA) patients have been treated with the following:
  - Anakinra (Kineret)
  - Canakinumab (Ilaris)

**Response:**

- Hywel Dda University Health Board (UHB) provides, within the table overleaf, the number of patients that have been treated with the listed medications for any condition, as recorded on the UHB's Pharmacy and Homecare systems, during the period 1 December 2022 to 30 November 2023.

Medication	Number
Anakinra (Kineret)	13
Canakinumab (Ilaris)	0

- & 3. The UHB is unable to provide you with the information requested, due to the low number of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. Therefore, the UHB is withholding these details under Section 40(2) of the Freedom of Information Act 2000 (FoIA).

This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.